


HPAPI 2020 conference to discuss containment solutions and ADC developments

The Highly Potent Active Pharmaceutical Ingredients conference will explore realworld examples of PBD payload synthesis and manufacture of oncology products.

LONDON, UNITED KINGDOM, February 10, 2020 /EINPresswire.com/ -- On the 11th – 12th May 2020, industry professionals will convene in London to discuss the challenges of the <u>HPAPI</u> industry at the Highly Potent Active Pharmaceutical Ingredients conference.

The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).

With this in mind, one of the underlying subjects of the conference will be on containment solutions and ADC developments, where real-world examples of PBD payload synthesis,



Highly Potent Active Pharmaceutical Ingredients 2020

manufacture of oncology products and design of ADC containment systems will be discussed in fine detail. The conference will feature three briefings dedicated to these topics from leading industry professionals:

1) CMC Strategies for the Timely Launch Preparation of Antibody-Drug-Conjugates as High Potent APIs

- •The manufacture of highly potent ADCs challenges and solutions
- •Deciding when to outsource and when to keep in-house
- •Bayer's ADC production concept

•Best practices for CMO selection and outsourcing ADC development and manufacture •The journey from development to launch - understanding the needs, solutions, risks and mitigations

Presented by Ulrich Ruemenapp, Head of Launch preparation and Coordination, Bayer Ag

2) Engineering in Support of ADC Containment – a Case Study

- •Innovative solutions to dealing with increasing toxicity of ADCs
- Designing ADC containment systems
- •The containment of ADCs a case study from AZ

Presented by Peter Marshall, Associate Éngineering Director, AstraZeneca

3) Manufacturing of Oncological Products: a Perspective by a CDMo
•New Product Introduction
•Cross Contamination Risk Assessment & Environmental Risk Assessment
•Clase Study: ADC Manufacturing
Presented by Fabio Zenobi, EHS Director, BSP Pharmaceuticals

Interested parties can view the full agenda and register for the event online at <u>http://www.highlypotentapi.com/pr2</u>

--- END ---

Highly Potent Active Pharmaceutical Ingredients Main conference: 11th-12th May 2020 Post-conferenc e workshop day: 13th May 2020 London, UK Sponsored by: BSP Pharmaceuticals To sponsor or exhibit at the conference, please contact Alia Malick on +44 (0) 207 827 6748

For all delegate enquiries, contact Dylan Brohm on +44 (0) 20 7827 1024.

Neill Howard SMi Group Ltd +44 20 7827 6000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.